Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients on recommended background therapies with heart rates ≥75 bpm and <75 bpm in the SHIFT trial. A cut-off value of ≥75 bpm was chosen by the EMEA for approval for the use of ivabradine in chronic heart failure.Methods The SHIFT population was divided by baseline heart rate ≥75 or <75 bpm. The effect of ivabradine was analysed for primary composite endpoint (cardiovascular death or HF hospitalization) and other endpoints.Results In the ≥75 bpm group, ivabradine reduced primary endpoint (HR 0.76, 95 % CI 0.68-0.85, P < 0.0001), all-cause mortality (HR 0.83, 95 % CI, 0.72-0.96, P = 0.0109), cardiovascular mortality (HR 0.83, 95 % CI, (0.71-0.97, P = 0.0166), HF death (HR 0.61, 95 % CI, 0.46-0.81, P < 0.0006), and HF hospitalization (HR 0.70, 95 % CI, 0.61-0.80, P < 0.0001). Risk reduction depended on heart rate after 28 days, with the best protection for heart rates <60 bpm or reductions >10 bpm. None of the endpoints was significantly reduced in the <75 bpm group, though there were trends for risk reductions in HF death and hospitalization for heart rate <60 bpm and reductions >10 bpm. Ivabradine was tolerated similarly in both groups.Conclusion The effect of ivabradine on outcomes is greater in patients with heart rate ≥75 bpm with heart rates achieved <60 bpm or heart rate reductions >10 bpm predicting best risk reduction. Our findings emphasize the importance of identification of high-risk HF patients by high heart rates and their treatment with heart rate-lowering drugs such as ivabradine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that most titration of β-blockade occurs early in the course of treatment, with most of the heart rate reduction occurring at < 50% of target dose.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [62]
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationCleland, J. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,549
Böhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Kolloch, R., Legler, U. F., Champion, A., Cooper-DeHoff, R. M., Handberg, E., Zhou, Q., & Pepine, C. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehn123 · Cited by 330
Conway, M. A., Allis, J., Ouwerkerk, R., Niioka, T., Rajagopalan, B., & Radda, G. K. (1991) · The Lancet · doi:10.1016/0140-6736(91)91838-l · Cited by 322
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr311 · Cited by 300
Self-citationMulder, P., Barbier, S., Chagraoui, A., Richard, V., Henry, J. P., Lallemand, F., Renet, S., Lerebours, G., Mahlberg-Gaudin, F., & Thuillez, C. (2004) · Circulation · doi:10.1161/01.cir.0000118464.48959.1c · Cited by 294
Current-dependent Block of Rabbit Sino-Atrial Node If Channels by Ivabradine
Bucchi, A., Baruscotti, M., & DiFrancesco, D. (2002) · The Journal of General Physiology · doi:10.1085/jgp.20028593 · Cited by 289
Custodis, F., Baumhäkel, M., Schlimmer, N., List, F., Gensch, C., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.746537 · Cited by 263
Self-citation
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Self-citation2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Metadata
- Authors
- Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- SUNY Downstate Health Sciences University (US)
- University of Glasgow (GB)
- Hospital Universitario La Paz (ES)
- University of Gothenburg (SE)
- Maria Cecilia Hospital (IT)
- Corresponding author
- Böhm, Michael
- Reil, Jan-Christian
- ORCID
- Venue
- Clinical Research in Cardiology
- Published
- 2012-05-11
- Volume
- 102
- Issue
- 1
- Pages
- 11-22
- ISSN
- 1861-0684 (ISSN-L)
- 1861-0692
- OpenAlex
- W2045247934
- Cited by
- 248
- References
- 18
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 15 · 2023: 15 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 34 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 10
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Clinical Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- ivabradine, chronic heart failure, baseline heart rate, SHIFT trial, cardiovascular mortality, heart failure hospitalization, heart rate reduction, all-cause mortality
- MeSH terms
- Ivabradine, Aged, Anti-Arrhythmia Agents, Benzazepines, Chronic Disease, Double-Blind Method, Female, Heart Failure, Heart Rate, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease Progression, Risk Assessment, Patient Selection, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. https://app.cochat.ai/papers/10.1007/s00392-012-0467-8
- The paper
- Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L. (2013). Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-012-0467-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.